• Home
• COVID-19
• EHA Statement on COVID-19 Vaccines
• Other Useful Resources

Other Useful Resources

Latest EMA publications on COVID-19 vaccines

• COVID-19 Vaccine Janssen: update on safety issues
• First COVID-19 vaccine approved for children aged 12 to 15 in EU
• Insufficient data on use of inhaled corticosteroids to treat COVID-19
• EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19
• Vaxzevria (AstraZeneka): further advice on blood clots and low blood platelets
• More flexible storage conditions for BioNTech/Pfizer’s COVID-19 vaccine
• AstraZeneca European Public Assessment Report (EPAR)
• EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen
• EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV)
• Clarification on Sputnik V vaccine in the EU approval process
• EMA preparing guidance to tackle COVID-19 variants

ERIC guidelines on COVID-19 vaccines (endorsed by EHA)

• SARS-CoV-2 Vaccine in Patients with CLL

COVID-19 vaccination guidance for people with bleeding disorders

• Guidance from the World Federation of Hemophilia (WFH), European Association for Haemophilia and Allied Disorders (EAHAD), European Haemophilia Consortium (EHC), and U.S. National Hemophilia Foundation (NHF) 

Vaccelerate, the new EU-funded platform on the planning and execution of clinical trials, offering a central point of contact for all stakeholders, from national health services to vaccine developers

• Provide core trial site characteristics and vaccine trial preferences of your center by filling in the questionnaire. The information provided in the questionnaire will be used to contact sites when VACCELERATE is asked to support.